TARA — Protara Therapeutics, Inc.
Healthcare • Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is...…
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $6.87
- Day High
- $5.71
- Day Low
- $5.07
- 52w High
- $7.82
- 52w Low
- $2.77
- Volume
- 6,465,027
- Avg Volume
- Beta
- 1.384
* TTM/most recent where available
Company
- Ticker
- TARA
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Jesse Shefferman
- Employees
- 28
- Website
- www.protaratx.com
Key Metrics
- Market Cap
- 215M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).